Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab biosimilar - Samsung Bioepis

Next Previous
Search
Drug Profile

Ranibizumab biosimilar - Samsung Bioepis

Alternative Names: Amelivu; BYOOVIZ; SB-11

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samsung Bioepis
  • Developer Biogen; Samsung Bioepis
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Registered Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 31 Oct 2024 Biogen terminates its licence for aflibercept biosimilar in USA and Canada
  • 12 Dec 2023 Samsung Bioepis completes a phase II trial for Neovascular wet age-related macular degeneration or Macular edema in Poland (NCT06176963)
  • 21 Nov 2023 Samsung Bioepis initiates a phase II trial for Neovascular wet age-related macular degeneration or Macular edema in Poland (NCT06176963)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top